Next Article in Journal
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Previous Article in Journal
Immune Checkpoint Inhibitors in Genitourinary Malignancies
 
 
Due to planned maintenance work on our platforms, there might be short service disruptions on Saturday, December 3rd, between 15:00 and 16:00 (CET).
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Immuno-Oncology—The New Paradigm of Lung Cancer Treatment

1
Department of Medical Oncology and Hematology, CancerCare Manitoba, and Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
2
Department of Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s2), 78-86; https://doi.org/10.3747/co.27.5183
Received: 7 January 2020 / Revised: 4 February 2020 / Accepted: 2 March 2020 / Published: 1 April 2020

Abstract

Systemic therapy is an essential part of treatment for all patients with small-cell lung cancer (sclc) and for most patients with non-small-cell lung cancer (nsclc). Standards of care have evolved dramatically since 2009, especially in the setting of incurable or advanced nsclc. Part of that evolution has been the incorporation of immuno-oncology drugs, especially immune checkpoint inhibitors (icis) into multiple therapeutic scenarios. In the present review, we discuss the role of the immune system in lung cancer and the previous failures of immunotherapy for patients with lung cancer. We then provide an overview of the existing evidence for the use of icis in patients with advanced nsclc that is either treatment-naïve or pretreated, for consolidative treatment after chemoradiotherapy in stage iii nsclc, and for palliative therapy in patients with sclc. Finally, we discuss duration of treatment, special populations, and the future of immuno-oncology for patients with lung cancer. Overall, we provide an evidence-based snapshot of immuno-oncology agents in the treatment of lung cancer up to early 2019.
Keywords: immuno-oncology; lung cancer; immunotherapy; PD-1; PD-L1 immuno-oncology; lung cancer; immunotherapy; PD-1; PD-L1

Share and Cite

MDPI and ACS Style

Dawe, D.E.; Harlos, C.H.; Juergens, R.A. Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. Curr. Oncol. 2020, 27, 78-86. https://doi.org/10.3747/co.27.5183

AMA Style

Dawe DE, Harlos CH, Juergens RA. Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. Current Oncology. 2020; 27(s2):78-86. https://doi.org/10.3747/co.27.5183

Chicago/Turabian Style

Dawe, D.E., C.H. Harlos, and R.A. Juergens. 2020. "Immuno-Oncology—The New Paradigm of Lung Cancer Treatment" Current Oncology 27, no. s2: 78-86. https://doi.org/10.3747/co.27.5183

Article Metrics

Back to TopTop